Skip to main content

Imago BioSciences, Inc. (IMGO)

NASDAQ: IMGO · IEX Real-Time Price · USD
25.53 0.22 (0.87%)
Oct 21, 2021 1:20 PM EDT - Market open
Market Cap822.04M
Revenue (ttm)n/a
Net Income (ttm)-20.70M
Shares Out32.20M
EPS (ttm)-0.64
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume20,318
Open25.18
Previous Close25.31
Day's Range24.50 - 25.86
52-Week Range14.99 - 35.68
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About IMGO

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing internally-discovered novel inhibitors and degraders of LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow, to improve the quality of life of patients with cancer and bone marrow diseases, in addition to prolonging their lives. Our lead product candidate is bomedemstat for the treatment of certain myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow. The three most common...

IndustryBiotechnology
IPO DateJul 16, 2021
CEOHugh Y. Rienhoff, Jr., M.D.
Employees17
Stock ExchangeNASDAQ
Ticker SymbolIMGO
Full Company Profile

Financial Performance

Financial Statements

News

Imago BioSciences Announces Its Addition to the Russell 2000® Index

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO--Imago BioSciences Announces Its Addition to the Russell 2000® Index

1 month ago - Business Wire

Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferati...

2 months ago - Business Wire

Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Ess...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #EMA--Imago BioSciences Receives Orphan Designation from European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia

2 months ago - Business Wire

Imago BioSciences, Inc. Announces Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (“Imago”) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferati...

2 months ago - Business Wire

Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ImagoBioSciences--Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering

3 months ago - Business Wire

Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #IMGO--Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

3 months ago - Business Wire

Imago BioSciences IPO Registration Document (S-1)

Imago BioSciences, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC